Dix Caroline, Tran Huyen
MBBS, MSc, FRACP, FRCPA, Thrombosis/Haemostasis Research Fellow, Department of Clinical Haematology, The Alfred Hospital, Melbourne, Vic.
MBBS (Hons), MasterClinEpi, FRACP, FRCPA, Director, Thrombosis/Haemostasis Unit and Haemophilia Treatment Centre, The Alfred Hospital, Melbourne, Vic; Professor, Australian Centre for Blood Diseases, Monash University, Melbourne, Vic.
Aust J Gen Pract. 2022 Sep;51(9):667-671. doi: 10.31128/AJGP-05-22-6440.
Pulmonary embolism (PE) remains a common problem and can present with nonspecific symptoms and signs. Anticoagulation is the mainstay of management, the duration of which often depends on the clinical circumstances of the PE.
The aim of this article is to review the epidemiology, clinical presentation, diagnosis, management and long-term complications of PE.
The incidence of PE appears to be increasing worldwide. Common risk factors include recent surgery, trauma, malignancy and oestrogen exposure. Diagnosis relies on a combination of clinical findings, laboratory tests and radiological imaging, often incorporating clinical prediction tools. Objectively confirmed PE requires anticoagulation, usually with a direct oral anticoagulant (DOAC), of at least three months' duration, but indefinite anticoagulation is being considered increasingly because of the heightened risk for recurrence following anticoagulation cessation, and overall safety of DOACs. Chronic thromboembolic pulmonary hypertension is rare but associated with significant morbidity and mortality.
肺栓塞(PE)仍然是一个常见问题,可表现为非特异性症状和体征。抗凝治疗是主要的治疗方法,其疗程通常取决于肺栓塞的临床情况。
本文旨在综述肺栓塞的流行病学、临床表现、诊断、治疗及长期并发症。
全球范围内,肺栓塞的发病率似乎在上升。常见的危险因素包括近期手术、创伤、恶性肿瘤和雌激素暴露。诊断依赖于临床发现、实验室检查和影像学检查相结合,通常会使用临床预测工具。经客观证实的肺栓塞需要抗凝治疗,通常使用直接口服抗凝剂(DOAC),疗程至少三个月,但由于抗凝治疗停止后复发风险增加以及DOAC的总体安全性,越来越多地考虑进行长期抗凝治疗。慢性血栓栓塞性肺动脉高压很少见,但与显著的发病率和死亡率相关。